Back to Search
Start Over
Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes
- Source :
- Plus Company Updates. March 30, 2022
- Publication Year :
- 2022
-
Abstract
- SHANGHAI: Antengene Corporation Limited has issued the following news release: Antengene Corporation Limited ('Antengene' SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.699168966